Numico CFO
This article was originally published in The Tan Sheet
Executive Summary
Jean-Marc Huet's selection as CFO, member of executive board will be proposed to shareholders during May 9 meeting, Dutch firm says Feb. 13. Announcement follows same-day statement that Royal Numico and current CFO Pim Oomens "are discussing his resignation"; further details were not released. Huet most recently "had co-responsibility" for Goldman Sachs' Netherlands office. Oomens had joined Numico in 1988 and became CFO in 2001. Management change follows a series of personnel shifts as Numico evaluates its U.S. operations (1"The Tan Sheet" Feb. 3, 2003, In Brief)...
You may also be interested in...
Numico personnel
Peter van Wel leaves company after serving under temporary contract as member of executive board responsible for U.S. operations, Dutch firm announces Jan. 30. Personnel change is part of Royal Numico's effort to "redefine the responsibilities of the U.S. management team" following firm's announcement it will divest Rexall Sundown (1"The Tan Sheet" Nov. 11, 2002, p. 3). Numico is looking for a successor with retail experience to focus on GNC, which was put on "probation" and could face divestiture if its financial performance does not improve. Van Well's successor also will be charged with executing the divestments...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.